Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica
Published in: Acta Neuropathologica 6/2012

Open Access 01-12-2012 | Review

Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited

Authors: Karl H. Plate, Alexander Scholz, Daniel J. Dumont

Published in: Acta Neuropathologica | Issue 6/2012

Login to get access

Abstract

The cellular and molecular mechanisms of tumor angiogenesis and its prospects for anti-angiogenic cancer therapy are major issues in almost all current concepts of both cancer biology and targeted cancer therapy. Currently, (1) sprouting angiogenesis, (2) vascular co-option, (3) vascular intussusception, (4) vasculogenic mimicry, (5) bone marrow-derived vasculogenesis, (6) cancer stem-like cell-derived vasculogenesis and (7) myeloid cell-driven angiogenesis are all considered to contribute to tumor angiogenesis. Many of these processes have been described in developmental angiogenesis; however, the relative contribution and relevance of these in human brain cancer remain unclear. Preclinical tumor models support a role for sprouting angiogenesis, vascular co-option and myeloid cell-derived angiogenesis in glioma vascularization, whereas a role for the other four mechanisms remains controversial and rather enigmatic. The anti-angiogenesis drug Avastin (Bevacizumab), which targets VEGF, has become one of the most popular cancer drugs in the world. Anti-angiogenic therapy may lead to vascular normalization and as such facilitate conventional cytotoxic chemotherapy. However, preclinical and clinical studies suggest that anti-VEGF therapy using bevacizumab may also lead to a pro-migratory phenotype in therapy resistant glioblastomas and thus actively promote tumor invasion and recurrent tumor growth. This review focusses on (1) mechanisms of tumor angiogenesis in human malignant glioma that are of particular relevance for targeted therapy and (2) controversial issues in tumor angiogenesis such as cancer stem-like cell-derived vasculogenesis and bone-marrow-derived vasculogenesis.
Literature
1.
Adams RH, Eichmann A (2010) Axon guidance molecules in vascular patterning. Cold Spring Harb Perspect Biol 2(5):a001875PubMedCrossRef
2.
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302):964–967PubMedCrossRef
3.
Belcik JT, Qi Y, Kaufmann BA et al (2012) Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer. J Am Coll Cardiol 60(7):618–625PubMedCrossRef
4.
Benedito R, Roca C, Sörensen I, Adams S, Gossler A, Fruttiger M, Adams RH (2009) The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137(6):1124–1135PubMedCrossRef
5.
Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, Duarte A, Pytowski B, Adams RH (2012) Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF–VEGFR2 signalling. Nature 484(7392):110–114PubMedCrossRef
6.
Benjamin LE, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125(9):1591–1598PubMed
7.
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592–603PubMedCrossRef
8.
Blanco R, Gerhardt H (2012) VEGF and Notch in tip and stalk cell selection. Cold Spring Harb Perspect Med October 1–20 (published online)
9.
10.
Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, Devi SN, Kaur B, Van Meir EG (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64(3):920–927PubMedCrossRef
11.
Broholm H, Laursen H (2004) Vascular endothelial growth factor (VEGF) receptor neuropilin-1’s distribution in astrocytic tumors. APMIS 112(4–5):257–263PubMedCrossRef
12.
Brown JL, Cao ZA, Pinzon-Ortiz M et al (2010) A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 9(1):145–156PubMedCrossRef
13.
Cao L, Jiao X, Zuzga DS, Liu Y, Fong DM, Young D, During MJ (2004) VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 36(8):827–835PubMedCrossRef
14.
Carmeliet P, Ferreira V, Breier G et al (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380(6573):435–439PubMedCrossRef
15.
Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298–307PubMedCrossRef
16.
Carmeliet P, De Smet F, Loges S, Mazzone M (2009) Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 6(6):315–326PubMedCrossRef
17.
Cascone T, Heymach JV (2012) Targeting the Angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword? J Clin Oncol 30(4):441–444PubMedCrossRef
18.
Chae SS, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemeyer E, de Graaf AMA, Sorensen AG, Munn LL, Jain RK, Fukumura D (2010) Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 16(14):3618–3627PubMedCrossRef
19.
Chamberlain MC (2011) Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 5:117–129PubMedCrossRef
20.
21.
Coffelt SB, Tal AO, Scholz A et al (2010) Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 70(13):5270–5280PubMedCrossRef
22.
Darland DC, Cain JT, Berosik MA, Saint-Geniez M, Odens PW, Schaubhut GJ, Frisch S, Stemmer-Rachamimov A, Darland T, D’Amore PA (2011) Vascular endothelial growth factor (VEGF) isoform regulation of early forebrain development. Dev Biol 358(1):9–22PubMedCrossRef
23.
De Bock K, Cauwenberghs S, Carmeliet P (2010) Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 21(1):1–7
24.
de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12(3):233–242PubMedCrossRef
25.
de Groot JF, Piao Y, Tran H et al (2011) Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 17(14):4872–4881PubMedCrossRef
26.
27.
De Palma M, Coukos G, Semela D (2012) TIE2-expressing monocytes: A novel cellular biomarker for hepatocellular carcinoma? Hepatology. doi:10.​1002/​hep.​26025
28.
De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE (2007) Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 28(12):519–524PubMedCrossRef
29.
De Palma M, Venneri MA, Galli R, Sergi LS, Politi LS, Sampaolesi M, Naldini L (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3):211–226PubMedCrossRef
30.
31.
Dieterich LC, Mellberg S, Langenkamp E et al (2012) Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFβ2 in vascular abnormalization. J Pathol. doi:10.​1002/​path.​4072
32.
Djonov V, Schmid M, Tschanz SA, Burri PH (2000) Intussusceptive angiogenesis: its role in embryonic vascular network formation. Circ Res 86(3):286–292PubMedCrossRef
33.
Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, Breitman ML (1994) Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8(16):1897–1909PubMedCrossRef
34.
Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J, Breitman ML (1992) tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 7(8):1471–1480PubMed
35.
Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3):232–239PubMedCrossRef
36.
Eckerich C, Zapf S, Fillbrandt R, Loges S, Westphal M, Lamszus K (2007) Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer 121(2):276–283PubMedCrossRef
37.
38.
Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2(10):795–803PubMedCrossRef
39.
Fiedler U, Reiss Y, Scharpfenecker M et al (2006) Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 12(2):235–239PubMedCrossRef
40.
Fischer C, Jonckx B, Mazzone M et al (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131(3):463–475PubMedCrossRef
41.
42.
Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376(6535):66–70PubMedCrossRef
43.
Fong GH, Zhang L, Bryce DM, Peng J (1999) Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 126(13):3015–3025PubMed
44.
Francescone R, Scully S, Bentley B, Yan W, Taylor SL, Oh D, Moral L, Shao R (2012) Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem 287(29):24821–24831PubMedCrossRef
45.
Goede V, Coutelle O, Neuneier J et al (2010) Identification of serum Angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 103(9):1407–1414PubMedCrossRef
46.
Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WKA (2008) VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 10(6):940–945PubMedCrossRef
47.
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899PubMedCrossRef
48.
Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Yung S, Chimenti S, Landsman L, Abramovitch R, Keshet E (2006) VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124(1):175–189PubMedCrossRef
49.
Hamerlik P, Lathia JD, Rasmussen R et al (2012) Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med 209(3):507–520PubMedCrossRef
50.
51.
Hatva E, Kaipainen A, Mentula P, Jääskeläinen J, Paetau A, Haltia M, Alitalo K (1995) Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol 146(2):368–378PubMed
52.
He T, Smith N, Saunders D et al (2011) Molecular MRI assessment of vascular endothelial growth factor receptor-2 in rat C6 gliomas. J Cell Mol Med 15(4):837–849PubMedCrossRef
53.
Herbst RS, Hong D, Chap L et al (2009) Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27(21):3557–3565PubMedCrossRef
54.
Ho IA, Toh HC, Ng WH, Teo YL, Guo CM, Hui KM, Lam PY (2012) Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells. doi:10.​1002/​stem.​1247
55.
Holash J (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99(17):11393–11398PubMedCrossRef
56.
Holash J, Wiegand SJ, Yancopoulos GD (1999) New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18(38):5356–5362PubMedCrossRef
57.
Holopainen T, Saharinen P, D’Amico G et al (2012) Effects of Angiopoietin-2-blocking antibody on endothelial cell–cell junctions and lung metastasis. J Natl Cancer Inst 104(6):461–475PubMedCrossRef
58.
Huang H, Bhat A, Woodnutt G, Lappe R (2010) Targeting the ANGPT–TIE2 pathway in malignancy. Nat Rev Cancer 10(8):575–585PubMedCrossRef
59.
Huang H, Lai J-Y, Do J et al (2011) Specifically targeting Angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 17(5):1001–1011PubMedCrossRef
60.
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58–62PubMedCrossRef
61.
62.
63.
Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA (2002) Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 99(18):11946–11950PubMedCrossRef
64.
Jones N, Iljin K, Dumont DJ, Alitalo K (2001) Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2(4):257–267PubMedCrossRef
65.
Jubb AM, Browning L, Campo L, Turley H, Steers G, Thurston G, Harris AL, Ansorge O (2012) Expression of vascular Notch ligands Delta-like 4 and Jagged-1 in glioblastoma. Histopathology 60(5):740–747PubMedCrossRef
66.
67.
Kerber M, Reiss Y, Wickersheim A et al (2008) Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 68(18):7342–7351PubMedCrossRef
68.
Keunen O, Johansson M, Oudin A et al (2011) Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 108(9):3749–3754PubMedCrossRef
69.
70.
Kim KJ, Li B, Houck K, Winer J, Ferrara N (1992) The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7(1):53–64PubMedCrossRef
71.
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423):841–844PubMedCrossRef
72.
Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120(3):694–705PubMedCrossRef
73.
Koh YJ, Kim HZ, Hwang S-I et al (2010) Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18(2):171–184PubMedCrossRef
74.
Korn C, Augustin HG (2012) Born to die: blood vessel regression research coming of age. Circulation 125(25):3063–3065PubMedCrossRef
75.
Kozin SV, Duda DG, Munn LL, Jain RK (2011) Is vasculogenesis crucial for the regrowth of irradiated tumours? Nat Rev Cancer 11(7):532PubMedCrossRef
76.
Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG (2010) Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 70(14):5679–5685PubMedCrossRef
77.
Kuczynski EA, Patten SG, Coomber BL (2011) VEGFR2 expression and TGF-β signaling in initial and recurrent high-grade human glioma. Oncology 81(2):126–134PubMedCrossRef
78.
Kuhnert F, Kirshner JR, Thurston G (2011) Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vascular Cell 3(1):20PubMedCrossRef
79.
Kurozumi K, Ichikawa T, Onishi M, Fujii K, Date I (2012) Cilengitide treatment for malignant glioma: current status and future direction. Neurol Med Chir (Tokyo) 52(8):539–547CrossRef
80.
Kurz H, Korn J, Eggli PS, Huang R, Christ B (2001) Embryonic central nervous system angiogenesis does not involve blood-borne endothelial progenitors. J Comp Neurol 436(3):263–274PubMedCrossRef
81.
Kurz H, Korn J, Christ B (2004) Morphogenesis of embryonic CNS vessels. Cancer Treat Res 117:33–50PubMedCrossRef
82.
Kümpers P, Gueler F, David S et al (2011) The synthetic Tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Crit Care 15(5):R261PubMedCrossRef
83.
Lambrechts D, Storkebaum E, Morimoto M et al (2003) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34(4):383–394PubMedCrossRef
84.
Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML (2007) Autocrine VEGF signaling is required for vascular homeostasis. Cell 130(4):691–703PubMedCrossRef
85.
Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56(20):4625–4629PubMed
86.
Leow CC, Coffman K, Inigo I et al (2012) MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 40(5):1321–1330PubMed
87.
Leung SY, Chan AS, Wong MP, Yuen ST, Cheung N, Chung LP (1997) Expression of vascular endothelial growth factor and its receptors in pilocytic astrocytoma. Am J Surg Pathol 21(8):941–950PubMedCrossRef
88.
Lewis CE, De Palma M, Naldini L (2007) Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and Angiopoietin-2. Cancer Res 67(18):8429–8432PubMedCrossRef
89.
Liu X-M, Zhang Q-P, Mu Y-G, Zhang X-H, Sai K, Pang JC-S, Ng H-K, Chen Z-P (2011) Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol 105(2):173–179PubMedCrossRef
90.
Llovet JM, Peña CEA, Lathia CD, Shan M, Meinhardt G, Bruix J, SHARP Investigators Study Group (2012) Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18(8):2290–2300PubMedCrossRef
91.
Loges S, Schmidt T, Carmeliet P (2009) “Antimyeloangiogenic” therapy for cancer by inhibiting PlGF. Clin Cancer Res 15(11):3648–3653PubMedCrossRef
92.
Lu KV, Chang JP, Parachoniak CA et al (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22(1):21–35PubMedCrossRef
93.
Machein MR, Renninger S, de Lima-Hahn E, Plate KH (2003) Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol 13(4):582–597PubMedCrossRef
94.
Maisonpierre PC, Suri C, Jones PF et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322):55–60PubMedCrossRef
95.
Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, Trent JM, Meltzer PS, Hendrix MJ (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155(3):739–752PubMedCrossRef
96.
Matsubara T, Kanto T, Kuroda S et al (2012) TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlated with angiogenesis. Hepatology. doi:10.​1002/​hep.​25965
97.
Mazzieri R, Pucci F, Moi D et al (2011) Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19(4):431–433CrossRef
98.
McDonald DM, Foss AJ (2000) Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev 19(1–2):109–120PubMedCrossRef
99.
McDonald DM, Munn L, Jain RK (2000) Vasculogenic mimicry: how convincing, how novel, and how significant? Am J Pathol 156(2):383–388PubMedCrossRef
100.
101.
Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8(8):618–631PubMedCrossRef
102.
Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, Zagzag D, Eagan P, Gruber ML (2012) A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 116(2):341–345PubMedCrossRef
103.
Norden AD, Bartolomeo J, Tanaka S et al (2012) Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol 106(1):121–125PubMedCrossRef
104.
Norden AD, Drappatz J, Wen PY (2009) Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 5(11):610–620PubMedCrossRef
105.
Onishi M, Ichikawa T, Kurozumi K, Fujii K, Yoshida K, Inoue S, Michiue H, Chiocca EA, Kaur B, Date I (2012) Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology. doi:10.​1111
106.
Oosthuyse B, Moons L, Storkebaum E et al (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28(2):131–138PubMedCrossRef
107.
Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220–231PubMedCrossRef
108.
Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3(4):347–361PubMedCrossRef
109.
Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, de Groot JF (2012) Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol. doi:10.​1093/​neuonc/​nos158 PubMed
110.
111.
Plate KH, Breier G, Risau W (1994) Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 4(3):207–218PubMedCrossRef
112.
Plate KH, Breier G, Millauer B, Ullrich A, Risau W (1993) Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53(23):5822–5827PubMed
113.
Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359(6398):845–848PubMedCrossRef
114.
Plate KH, Breier G, Weich HA, Mennel HD, Risau W (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59(4):520–529PubMedCrossRef
115.
Raab S, Plate KH (2007) Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. Acta Neuropathol 113(6):607–626PubMedCrossRef
116.
Raab S, Beck H, Gaumann A, Yüce A, Gerber H-P, Plate K, Hammes H-P, Ferrara N, Breier G (2004) Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost 91(3):595–605PubMed
117.
Rapisarda A, Melillo G (2012) Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 9(7):378–390PubMedCrossRef
118.
Reis M, Czupalla CJ, Ziegler N et al (2012) Endothelial Wnt/ß-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med 209(9):1611–1627PubMedCrossRef
119.
Ribatti D, Djonov V (2012) Intussusceptive microvascular growth in tumors. Cancer Lett 316(2):126–131PubMedCrossRef
120.
Ricci-Vitiani L, Pallini R, Biffoni M et al (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468(7325):824–828PubMedCrossRef
121.
122.
Roca C, Adams RH (2007) Regulation of vascular morphogenesis by Notch signaling. Genes Dev 21(20):2511–2524PubMedCrossRef
123.
Rodriguez FJ, Orr BA, Ligon KL, Eberhart CG (2012) Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget 3(1):98–106PubMed
124.
125.
Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P (2009) Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 89(2):607–648PubMedCrossRef
126.
Scaringi C, Minniti G, Caporello P, Enrici RM (2012) Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Anticancer Res 32(10):4213–4223PubMed
127.
Schanzer A, Wachs F-P, Wilhelm D, Acker T, Cooper-Kuhn C, Beck H, Winkler J, Aigner L, Plate KH, Kuhn HG (2004) Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol 14(3):237–248PubMedCrossRef
128.
Scholz A, Lang V, Henschler R et al (2011) Angiopoietin-2 promotes myeloid cell infiltration in a β2-integrin-dependent manner. Blood 118(18):5050–5059PubMedCrossRef
129.
Sennino B, McDonald DM (2012) Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 12(10):699–709PubMedCrossRef
130.
Sennino B, Ishiguro-Oonuma T, Wei Y et al (2012) Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2(3):270–287PubMedCrossRef
131.
Seystahl K, Weller M (2012) Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? Expert Opin Investig Drugs 21(5):605–617PubMedCrossRef
132.
Shabo I, Olsson H, Sun X-F, Svanvik J (2009) Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time. Int J Cancer 125(8):1826–1831PubMedCrossRef
133.
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376(6535):62–66PubMedCrossRef
134.
Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359(6398):843–845PubMedCrossRef
135.
Sica A, Schioppa T, Mantovani A, Allavena P (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42(6):717–727PubMedCrossRef
136.
Sikkema AH, de Bont ESJM, Molema G, Dimberg A, Zwiers PJ, Diks SH, Hoving EW, Kamps WA, Peppelenbosch MP, den Dunnen WFA (2011) Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells. Neuropathol Appl Neurobiol 37(5):538–548PubMedCrossRef
137.
Sitohy B, Nagy JA, Dvorak HF (2012) Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 72(8):1909–1914PubMedCrossRef
138.
Sorensen AG, Emblem KE, Polaskova P et al (2012) Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72(2):402–407PubMedCrossRef
139.
Steidl C, Lee T, Shah SP et al (2010) Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 362(10):875–885PubMedCrossRef
140.
Storkebaum E, Lambrechts D, Dewerchin M et al (2005) Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8(1):85–92PubMedCrossRef
141.
Stratmann A, Risau W, Plate KH (1998) Cell type-specific expression of Angiopoietin-1 and Angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153(5):1459–1466PubMedCrossRef
142.
Thompson EM, Frenkel EP, Neuwelt EA (2011) The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 76(1):87–93PubMedCrossRef
143.
Tung JJ, Tattersall IW, Kitajewski J (2012) Tips, stalks, tubes: Notch-mediated cell fate determination and mechanisms of tubulogenesis during angiogenesis. Cold Spring Harb Perspect Med 2(2):a006601PubMed
144.
Valenzuela DM, Griffiths JA, Rojas J et al (1999) Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 96(5):1904–1909PubMedCrossRef
145.
van Agtmaal EL, Bierings R, Dragt BS, Leyen TA, Fernandez-Borja M, Horrevoets AJG, Voorberg J (2012) The shear stress-induced transcription factor KLF2 affects dynamics and Angiopoietin-2 content of Weibel-Palade bodies. PLoS One 7(6):e38399PubMedCrossRef
146.
Verheyen A, Peeraer E, Nuydens R et al (2012) Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy. Brain 135(Pt 9):2629–2641PubMedCrossRef
147.
Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729PubMedCrossRef
148.
Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C, Tabar V (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468(7325):829–833PubMedCrossRef
149.
Wick A, Wick W, Waltenberger J, Weller M, Dichgans J, Schulz JB (2002) Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci 22(15):6401–6407PubMed
150.
Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG (1997) Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 81(4):567–574PubMedCrossRef
151.
Xu L, Duda DG, di Tomaso E et al (2009) Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 69(20):7905–7910PubMedCrossRef
152.
Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, Niessen K, Plowman GD (2010) Chronic DLL4 blockade induces vascular neoplasms. Nature 463(7282):E6–E7PubMedCrossRef
153.
Yang X, Cepko CL (1996) Flk-1, a receptor for vascular endothelial growth factor (VEGF), is expressed by retinal progenitor cells. J Neurosci 16(19):6089–6099PubMed
154.
You W-K, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao L-C, Aftab DT, McDonald DM (2011) VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 71(14):4758–4768PubMedCrossRef
155.
Yue W-Y, Chen Z-P (2005) Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem 53(8):997–1002PubMedCrossRef
156.
Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88(11):2606–2618PubMedCrossRef
157.
Zhang BC, Gao J, Wang J, Rao ZG, Wang BC, Gao JF (2011) Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol 28(4):1447–1452PubMedCrossRef
Metadata
Title
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Authors
Karl H. Plate
Alexander Scholz
Daniel J. Dumont
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Acta Neuropathologica / Issue 6/2012
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-012-1066-5

Other articles of this Issue 6/2012

Acta Neuropathologica 6/2012 Go to the issue

Original Paper

Amyloid plaque formation precedes dendritic spine loss

Methods Paper

Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate

Editorial

The next step in brain tumor classification: “Let us now praise famous men”… or molecules?

Original Paper

LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR)

Correspondence

Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma

Original Paper

[18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies